We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease.
- Authors
Korakas, Emmanouil; Kountouri, Aikaterini; Pavlidis, George; Oikonomou, Evangelos; Vrentzos, Emmanouil; Michalopoulou, Eleni; Tsigkou, Vasiliki; Katogiannis, Konstantinos; Pliouta, Loukia; Balampanis, Konstantinos; Pililis, Sotirios; Malandris, Konstantinos; Tsapas, Apostolos; Siasos, Gerasimos; Ikonomidis, Ignatios; Lambadiari, Vaia
- Abstract
Context The cardiovascular benefits of semaglutide are established; however, its effects on surrogate vascular markers and liver function are not known. Objective To investigate the effects of semaglutide on vascular, endothelial, and liver function in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Methods Overall, 75 consecutive subjects with T2DM and NAFLD were enrolled: 50 patients received semaglutide 1 mg (treatment group) and 25 patients received dipeptidyl peptidase 4 inhibitors (control group). All patients underwent a clinical, vascular, and hepatic examination with Fibroscan elastography at 4 and 12 months after inclusion in the study. Results Treatment with semaglutide resulted in a reduction of Controlled Attenuation Parameter (CAP) score, E fibrosis score, NAFLD fibrosis score, Fibrosis-4 (FIB-4) score and perfused boundary region (PBR) at 4 and at 12 months (P <.05), contrary to controls. Patients treated with semaglutide showed a greater decrease of central systolic blood pressure (SBP) (−6% vs −4%, P =.048 and −11% vs −9%, P =.039), augmentation index (AIx) (−59% vs −52%, P =.041 and −70% vs −57%, P =.022), and pulse wave velocity (PWV) (−6% vs −3.5%, P =.019 and −12% vs −10%, P =.036) at 4 and at 12 months, respectively. In all patients, ΔPWV and ΔPBR were correlated with a corresponding reduction of CAP, E fibrosis, NAFLD fibrosis, and FIB-4 scores. Conclusion Twelve-month treatment with semaglutide simultaneously improves arterial stiffness, endothelial function, and liver steatosis and fibrosis in patients with T2DM and NAFLD.
- Subjects
NON-alcoholic fatty liver disease; FATTY liver; HEPATIC fibrosis; PULSE wave analysis; CD26 antigen
- Publication
Journal of the Endocrine Society, 2024, Vol 8, Issue 8, p1
- ISSN
2472-1972
- Publication type
Article
- DOI
10.1210/jendso/bvae122